The FDA recently approved Reblozyl.
Reblozyl reduced blood transfusion requirements by 33% in ~20% of patients, and by 50% in ~8%. A typical dose of Reblozyl consists of 1 mg of the drug for a kilogram of the patient's weight. A 75 mg vial of Reblozyl will be available at a wholesale acquisition cost of US$10,323.53 per vial. Dosing is every three weeks. This cost does not include hospital markup or admin fee.
General Comments / Chat, page-52
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.045(2.80%) |
Mkt cap ! $260.3M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.55 | $94.33K | 60.12K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1250 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 5000 | 1 |
View Market Depth
| Last trade - 14.37pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.56 |
Change
-0.045 ( 1.17 %) |
||||
| Open | High | Low | Volume | ||
| $1.58 | $1.59 | $1.55 | 8174 | ||
| Last updated 14.21pm 16/05/2024 ? | |||||
| RAC (ASX) Chart |